Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 3/20 | 0.36 |
| ▸ | JAK1 | P23458 | 3/20 | 0.36 |
| ▸ | TYK2 | P29597 | 3/20 | 0.36 |
| ▸ | JAK3 | P52333 | 3/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1703536 | 1.00 | ACHE (0.42) | ACHEMAPTLMNAL3MBTL1ALDH1A1 | |
| SCHEMBL15894907 | 1.00 | ACHE (0.42) | ACHEMAPTLMNAL3MBTL1ALDH1A1 | |
| SCHEMBL15651008 | 0.87 | ACHE (0.41) | ACHEMAPTLMNAL3MBTL1ALDH1A1 | |
| SCHEMBL2729216 | 0.84 | ACHE (0.53) | ACHEMAPTLMNAL3MBTL1ALDH1A1 | |
| SCHEMBL24884483 | 0.83 | MAPT (0.40) | ACHEMAPTLMNAL3MBTL1ALDH1A1 | |
| SCHEMBL30190756 | 0.83 | MAPT (0.40) | ACHEMAPTLMNAL3MBTL1ALDH1A1 | |
| SCHEMBL4515387 | 0.81 | MAPT (0.42) | ACHEMAPTLMNAL3MBTL1ALDH1A1 | |
| SCHEMBL1703997 | 0.79 | MAPT (0.40) | MAPTLMNAL3MBTL1ALDH1A1PKM | |
| SCHEMBL15973719 | 0.79 | MAPT (0.40) | MAPTLMNAL3MBTL1ALDH1A1PKM | |
| SCHEMBL1703543 | 0.79 | MAPT (0.40) | MAPTLMNAL3MBTL1ALDH1A1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116887-A1 | HETEROCYCLIC COMPOUNDS FOR MEDIATING TYROSINE KINASE 2 ACTIVITY | GUANGZHOU INNOCARE PHARMA TECH CO LTD (CN) | 2026-04-30 | — | — | US | disclosed |
| US-12448382-B2 | Heterocyclic compounds for mediating tyrosine kinase 2 activity | GUANGZHOU INNOCARE PHARMA TECH CO. LTD. (CN) | 2025-10-21 | — | — | US | disclosed |
| US-20240190849-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF THEIR USE | TYRA BIOSCIENCES, INC. | 2024-06-13 | — | — | US | disclosed |
| CN-114096532-B | Heterocyclic compounds which inhibit tyrosine kinase 2 activity | 广州诺诚健华医药科技有限公司 | 2023-12-01 | — | — | CN | disclosed |
| CN-117136184-A | Aminopyrimidine compounds and methods of use thereof | 泰拉生物科学公司 | 2023-11-28 | — | — | CN | disclosed |
| US-11655252-B2 | Aminopyrimidinyl derivatives | PFIZER INC. (US) | 2023-05-23 | — | — | US | disclosed |
| CN-115996930-A | Aminopyrimidinyl derivatives | 辉瑞公司 | 2023-04-21 | — | — | CN | disclosed |
| US-20230009626-A1 | INDOLINONE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | ICHNOS SCIENCES S.A. (CH) | 2023-01-12 | — | — | US | disclosed |
| US-20220112200-A1 | HETEROCYCLIC COMPOUNDS FOR MEDIATING TYROSINE KINASE 2 ACTIVITY | GUANGZHOU INNOCARE PHARMA TECH CO., LTD. (CN) | 2022-04-14 | — | — | US | disclosed |
| CN-114096532-A | Heterocyclic compounds inhibiting tyrosine kinase 2 activity | 广州诺诚健华医药科技有限公司 | 2022-02-25 | — | — | CN | disclosed |
| CN-102498110-A | 2- (LH-pyrazol-4-ylamino) -pyrimidine as kinase inhibitors | ABBOTT LAB | 2012-06-13 | — | — | CN | disclosed |
| EP-2440548-A1 | 2- ( LH-PYRAZOL-4 -YLAMINO ) -PYRIMIDINE AS KINASE INHIBITORS | Abbott Laboratories (US) | 2012-04-18 | — | — | EP | disclosed |
| CN-102131389-A | Triazolopyridine JAK inhibitor compounds and methods | GENENTECH INC | 2011-07-20 | — | — | CN | disclosed |
| WO-2011048082-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2011-04-28 | — | — | WO | disclosed |
| EP-2288260-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | Genentech, Inc. (US) | 2011-03-02 | — | — | EP | disclosed |
| US-20100317680-A1 | PYRIMIDINE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2010-12-16 | — | — | US | disclosed |
| WO-2010144468-A1 | 2- ( LH-PYRAZOL-4 -YLAMINO ) -PYRIMIDINE AS KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2010-12-16 | — | — | WO | disclosed |
| WO-2010100070-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2010-09-10 | — | — | WO | disclosed |
| US-20100048557-A1 | Triazolopyridine JAK Inhibitor Compounds and Methods | GENENTECH, INC. | 2010-02-25 | — | — | US | disclosed |
| WO-2009155551-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317680-A1 | PYRIMIDINE INHIBITORS OF KINASES | AURKA, AURKC, AURKB | ACHE 3247/4885MAPT 2310/4885LMNA 2413/4885 |
| US-11655252-B2 | Aminopyrimidinyl derivatives | JAK2, JAK1, JAK3 | ACHE 4853/4885MAPT 2409/4885LMNA 4722/4885 |
| US-20100048557-A1 | Triazolopyridine JAK Inhibitor Compounds and Methods | JAK2, JAK1, JAK3 | ACHE 4002/4885MAPT 608/4885LMNA 4580/4885 |
| US-20220112200-A1 | HETEROCYCLIC COMPOUNDS FOR MEDIATING TYROSINE KINASE 2 ACTIVITY | TYK2, JAK2, JAK1 | ACHE 4829/4885MAPT 3694/4885LMNA 4667/4885 |
| US-20260116887-A1 | HETEROCYCLIC COMPOUNDS FOR MEDIATING TYROSINE KINASE 2 ACTIVITY | TYK2, JAK2, JAK1 | ACHE 4835/4885MAPT 4419/4885LMNA 4597/4885 |
| US-20230009626-A1 | INDOLINONE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | MAP4K1, MAP4K2, MAP4K4 | ACHE 3708/4885MAPT 142/4885LMNA 1226/4885 |
| US-12448382-B2 | Heterocyclic compounds for mediating tyrosine kinase 2 activity | TYK2, JAK2, JAK1 | ACHE 4829/4885MAPT 3694/4885LMNA 4667/4885 |
| US-20240190849-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF THEIR USE | DPYD, TYMP, TYMS | ACHE 3879/4885MAPT 3848/4885LMNA 3644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.